fda tirzepatide compound Compounded (GLP-1/GIP) May 18, 2026: FDA warns

For each case (N = 289), two sex and age frequency-matched control subjects (N = 504) were randomly selected from the general population as registered in the regional registry office (Einwohnermeldeamt)

Throughout these extensive clinical development programs, seizures were not identified as an adverse event occurring at rates higher than expected in the general population

Study results have been mixed so far, and while weight loss can be significant, results are dependent on a range of variables, such as participants, type of drug used, comorbidities, length of use and target outcomes

Predrag Sikiric, [email protected] This article was submitted to Translational Pharmacology, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers